Having trouble accessing articles? Reset your cache.

Tecentriq-Avastin combo poised to become SOC for hepatocellular carcinoma

Tecentriq continues to carve out a niche in the crowded PD-1/PD-L1 space as new survival data for the drug in the combination with Avastin in hepatocellular carcinoma pave the way for the regimen to become standard of care.

On Friday, Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit unveiled data from the Phase III IMbrave150 study

Read the full 555 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE